{"title":"Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case report.","authors":"Sercan Ön","doi":"10.1080/1120009X.2025.2512262","DOIUrl":null,"url":null,"abstract":"<p><p>Gestational trophoblastic neoplasia (GTN) is a rare malignancy that can develop following a hydatidiform mole or a non-molar pregnancy and often presents with metastasis. Although conventional chemotherapy achieves remission in over 90% of metastatic cases some patients develop resistance. I report a 36-year-old woman with metastatic GTN after prolonged uterin bleeding and elevated β-hCG levels. Despite multiple chemotherapy regimens, including cisplatin/etoposide and EMA-CO, the patient did not achieve remission. After the failure of conventional chemotherapy, pembrolizumab, an immune checkpoint inhibitor, was introduced. This treatment resulted in a rapid decrease in β-hCG levels and a complete biochemical response. The treatment was well tolerated, only minor immune-related adverse events. After eight cycles of pembrolizumab, she remained in remission for one year. This case highlights the potential role of immunotherapy in managing chemoresistant metastatic GTN and underscores the need for further studies to establish its effectiveness in such situations.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-4"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2512262","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Gestational trophoblastic neoplasia (GTN) is a rare malignancy that can develop following a hydatidiform mole or a non-molar pregnancy and often presents with metastasis. Although conventional chemotherapy achieves remission in over 90% of metastatic cases some patients develop resistance. I report a 36-year-old woman with metastatic GTN after prolonged uterin bleeding and elevated β-hCG levels. Despite multiple chemotherapy regimens, including cisplatin/etoposide and EMA-CO, the patient did not achieve remission. After the failure of conventional chemotherapy, pembrolizumab, an immune checkpoint inhibitor, was introduced. This treatment resulted in a rapid decrease in β-hCG levels and a complete biochemical response. The treatment was well tolerated, only minor immune-related adverse events. After eight cycles of pembrolizumab, she remained in remission for one year. This case highlights the potential role of immunotherapy in managing chemoresistant metastatic GTN and underscores the need for further studies to establish its effectiveness in such situations.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
